Drugs / ITI-5000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07652242 | Jul 2026 → Feb 2028 expected | triple-negative breast carcinoma | Immunomic Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ITI-5000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652242 ↗ |
| Modality | Small activating RNA (saRNA) | “ITI-5000 is a self-amplifying RNA (saRNA) vaccine” NCT07652242 ↗ |
| Route | Intramuscular | “as an intramuscular injection” NCT07652242 ↗ |